Global PSMA Imaging Agent for Prostate Cancer Market Strategic Research Report

Scope of the Report

The global PSMA Imaging Agent for Prostate Cancer market size is predicted to grow from US$ 1,731 million in 2025 to US$ 2,839 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.

In 2025, the global production of PSMA imaging agent for prostate cancer reached 3.5394 million units, with an average selling price of $500 per unit. The annual production capacity of PSMA imaging agents for prostate cancer worldwide is approximately 5 million units, with a gross margin of about 30.4%. PSMA imaging agent for prostate cancer is a radiotracer that targets prostate‑specific membrane antigen (PSMA) and enables molecular‑level imaging of prostate cancer lesions via positron emission tomography (PET). PSMA is highly expressed on the surface of prostate cancer cells. After the imaging agent specifically binds to it, PET/CT or PET/MRI equipment is used to detect radioactive signals, thereby enabling high‑sensitivity localization of primary lesions, detection of metastases, and assessment of recurrence. It is currently an important tool in precision diagnosis and treatment of prostate cancer. The upstream of PSMA imaging agents for prostate cancer includes radionuclides (such as gallium‑68, fluorine‑18, etc.), PSMA‑targeting ligands (small molecules/peptides/antibodies), and nanocarriers/chelators, among others. The midstream consists of manufacturers of PSMA imaging agents for prostate cancer, while the downstream is mainly used in nuclear medicine and molecular imaging, precision tumor diagnosis, and radiopharmaceuticals and nuclear medicine.

Currently, the market for PSMA imaging agent for prostate cancer is in a phase of rapid development. As a revolutionary molecular imaging tool, it has been widely integrated into clinical management pathways for prostate cancer, playing a key role especially in initial staging, detection of biochemical recurrence, and formulation of treatment strategies. With the growing availability of PET/CT and PET/MRI equipment and the continuous emergence of novel PSMA ligands, the clinical applications of this imaging agent are steadily expanding. Meanwhile, the rise of the theranostics concept means that PSMA imaging agents for prostate cancer are not only used for diagnosis but are also beginning to be linked with PSMA‑targeted radionuclide therapy, ushering prostate cancer into a new era of precision medicine. Furthermore, improvements in regulatory approval and standardized production requirements for radiopharmaceuticals, along with gradual optimization of reimbursement policies, have further contributed to the maturation and growth of this market.

Report Scope

Key Questions Addressed in this Report

What is the 10-year outlook for the global PSMA Imaging Agent for Prostate Cancer market?

What factors are driving PSMA Imaging Agent for Prostate Cancer market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do PSMA Imaging Agent for Prostate Cancer market opportunities vary by end market size?

How does PSMA Imaging Agent for Prostate Cancer break out by Type, by Application?

This report presents a comprehensive overview of the global PSMA Imaging Agent for Prostate Cancer market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 68Ga
• 18F

Segment by Core Carrier Materials

• First Generation
• Second Generation

Segment by Mechanism of Action

• Active Targeting
• Passive Targeting

Segment by Application

• Nuclear Medicine and Molecular Imaging
• Precision Oncology Diagnostics
• Radiopharmaceuticals and Radiopharmaceuticals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global PSMA Imaging Agent for Prostate Cancer market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Nuclear Medicine and Molecular Imaging, Precision Oncology Diagnostics, Radiopharmaceuticals and Radiopharmaceuticals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact